MINNEAPOLIS - Rebecca Blix has been suffering from migraines since she was fifteen. At her worst she was having them every day.
“I would wake up and they would last up to seven days,” Blix says.
Like many people who suffer from migraines, she's been on a never-ending search for anything to help calm her symptoms.
“I've tried, honestly, probably over 60 drugs,” she says.
Now, there’s hope.
Dr. Gary Berman is leading an upcoming study at the Clinical Research Institute in downtown Minneapolis for a treatment called ALD403.
If it works like they hope it does, it would stop a migraine before it even starts.
“It's revolutionary. It'll change everything,” Berman says. “Right now the best things we have is something good to take when you have a migraine but nothing to prevent migraines.”
The drug blocks a protein called CGRP that's been shown to dilate blood vessels and cause migraines.
“Basically, it prevents those blood vessels from dilating,” Berman says.
The drug is given to patients through an IV once every three months.
Dr. Berman and his staff are looking for people who suffer from migraines to take part in the study, to make sure it works and is safe before it's approved by the FDA.
“This is probably the best thing we've done in twenty years,” says Berman.
For Rebecca, she hopes it's an answer to years of searching.
“It makes you feel like somebody is on your team,” she says. “It’s going to change lives.”
Dr. Berman says it will be at least a couple years before the drug hits the market.
If you’re interested in taking part in the study, call the Clinical Research Institute at 612-333-2200 (ext. 5).